Literature DB >> 16830335

Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.

Thomas De Raedt1, Ophélia Maertens, Magdalena Chmara, Hilde Brems, Ine Heyns, Raf Sciot, Elisa Majounie, Meena Upadhyaya, Sofie De Schepper, Frank Speleman, Ludwine Messiaen, Joris Robert Vermeesch, Eric Legius.   

Abstract

Neurofibromatosis type I (NF1) is an autosomal dominant familial tumor syndrome characterized by the presence of multiple benign neurofibromas. In 95% of NF1 individuals, a mutation is found in the NF1 gene, and in 5% of the patients, the germline mutation consists of a microdeletion that includes the NF1 gene and several flanking genes. We studied the frequency of loss of heterozygosity (LOH) in the NF1 region as a mechanism of somatic NF1 inactivation in neurofibromas from NF1 patients with and without a microdeletion. There was a statistically significant difference between these two patient groups in the proportion of neurofibromas with LOH. None of the 40 neurofibromas from six different NF1 microdeletion patients showed LOH, whereas LOH was observed in 6/28 neurofibromas from five patients with an intragenic NF1 mutation (P = 0.0034, Fisher's exact). LOH of the NF1 microdeletion region in NF1 microdeletion patients would de facto lead to a nullizygous state of the genes located in the deletion region and might be lethal. The mechanisms leading to LOH were further analyzed in six neurofibromas. In two out of six neurofibromas, a chromosomal microdeletion was found; in three, a mitotic recombination was responsible for the observed LOH; and in one, a chromosome loss with reduplication was present. These data show an important difference in the mechanisms of second hit formation in the 2 NF1 patient groups. We conclude that NF1 is a familial tumor syndrome in which the type of germline mutation influences the type of second hit in the tumors. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830335     DOI: 10.1002/gcc.20353

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

2.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

3.  Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.

Authors:  Tsung-Chieh Shih; Yunpeng Fan; Sophie Kiss; Xiaocen Li; Xiaojun Nicole Deng; Ruiwu Liu; Xiao-Jia Chen; Randy Carney; Amanda Chen; Paramita M Ghosh; Kit S Lam
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 4.  Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease).

Authors:  Marica Eoli; Donata Bianchessi; Anna Luisa Di Stefano; Elena Prodi; Elena Anghileri; Gaetano Finocchiaro
Journal:  Neurol Sci       Date:  2012-12       Impact factor: 3.307

5.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

6.  Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination.

Authors:  Katharina Steinmann; David N Cooper; Lan Kluwe; Nadia A Chuzhanova; Cornelia Senger; Eduard Serra; Conxi Lazaro; Montserrat Gilaberte; Katharina Wimmer; Viktor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

7.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

8.  Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Authors:  Doris Steinemann; Larissa Arning; Inka Praulich; Manfred Stuhrmann; Henrik Hasle; Jan Stary; Brigitte Schlegelberger; Charlotte M Niemeyer; Christian Flotho
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Authors:  Meena Upadhyaya; Gill Spurlock; Lan Kluwe; Nadia Chuzhanova; Emma Bennett; Nick Thomas; Abhijit Guha; Victor Mautner
Journal:  Neurogenetics       Date:  2009-02-17       Impact factor: 2.660

10.  Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1.

Authors:  Ophélia Maertens; Sofie De Schepper; Jo Vandesompele; Hilde Brems; Ine Heyns; Sandra Janssens; Frank Speleman; Eric Legius; Ludwine Messiaen
Journal:  Am J Hum Genet       Date:  2007-06-20       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.